

Trastuzumab Biosimilars Global Market Estimated To Grow At 27% Rate

*The Business Research Company's
Trastuzumab Biosimilars Global Market
Report 2022 – Market Size, Trends, And
Global Forecast 2022-2026*

LONDON, GREATER LONDON, UK,
October 14, 2022 /EINPresswire.com/ --
As per The Business Research
Company's "[Trastuzumab Biosimilars
Global Market Report 2022](#)", the

trastuzumab biosimilars market is expected to grow from \$2.08 billion in 2021 to \$2.64 billion in 2022 at a compound annual growth rate (CAGR) of 27.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The trastuzumab biosimilar market is expected to reach \$6.90 billion in 2026 at a CAGR of 27.1%. The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market.

Request a Sample now to gain a better understanding of trastuzumab biosimilars market:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp>

Key Trends In The Trastuzumab Biosimilars Market

Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers.

[Overview Of The Trastuzumab Biosimilars Market](#)

The trastuzumab biosimilar market consists of the sales of trastuzumab biosimilar and related services by entities (organizations, sole traders, and partnerships) that manufacture trastuzumab biosimilar. Trastuzumab is a monoclonal antibody that interferes with human epidermal growth factor receptor (HER2). Trastuzumab biosimilars are used mainly for the treatment of breast



The Business
Research Company

Trastuzumab Biosimilars Global Market Report 2022 –
Market Size, Trends, And Global Forecast 2022-2026

cancer and gastroesophageal junction adenocarcinoma or metastatic gastric.

Learn more on the global trastuzumab biosimilars market report at:

<https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report>

Trastuzumab Biosimilars Global Market Report 2022 from TBRC covers the following information:

Market Size Data

- Forecast period: Historical and Future
- By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Market Segmentation

- By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Others
- By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Others
- By Distribution Channel: Hospital Pharmacy, Online Pharmacy
- By Geography: The global trastuzumab biosimilars market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market.

Major market players such as Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc.

Trends, opportunities, strategies and so much more.

Trastuzumab Biosimilars Global Market Report 2022 is one of The Business Research Company's comprehensive reports that provides an overview of trastuzumab biosimilars market. The market report analyzes and trastuzumab biosimilars global market forecast market size, trastuzumab biosimilars global market growth drivers, trastuzumab biosimilars market share, trastuzumab biosimilars market segments, trastuzumab biosimilars market major players, trastuzumab biosimilars market growth across geographies, and trastuzumab biosimilars market competitors' revenues and market positioning. The trastuzumab biosimilars industry report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential.

Not what you were looking for? Go through similar reports by The Business Research Company: Biosimilar Therapeutic Peptides Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global->

[market-report](#)

Biosimilar Monoclonal Antibodies Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report>

Rituximab Biosimilars Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/rituximab-biosimilars-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 3000 industry reports, covering over 3000 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

TBRC Blog: <http://blog.tbrc.info/>

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/595917017>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.